Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Assets Average (2019 - 2025)

Historic Assets Average for BioNexus Gene Lab (BGLC) over the last 7 years, with Q3 2025 value amounting to $8.5 million.

  • BioNexus Gene Lab's Assets Average fell 2300.61% to $8.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year decrease of 2300.61%. This contributed to the annual value of $10.9 million for FY2024, which is 840.96% up from last year.
  • BioNexus Gene Lab's Assets Average amounted to $8.5 million in Q3 2025, which was down 2300.61% from $9.5 million recorded in Q2 2025.
  • Over the past 5 years, BioNexus Gene Lab's Assets Average peaked at $11.4 million during Q4 2023, and registered a low of $8.0 million during Q2 2023.
  • For the 5-year period, BioNexus Gene Lab's Assets Average averaged around $9.6 million, with its median value being $9.7 million (2021).
  • In the last 5 years, BioNexus Gene Lab's Assets Average surged by 82662.15% in 2021 and then plummeted by 2300.61% in 2025.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Assets Average stood at $9.7 million in 2021, then dropped by 14.48% to $8.3 million in 2022, then skyrocketed by 38.26% to $11.4 million in 2023, then fell by 6.28% to $10.7 million in 2024, then fell by 20.47% to $8.5 million in 2025.
  • Its Assets Average stands at $8.5 million for Q3 2025, versus $9.5 million for Q2 2025 and $10.0 million for Q1 2025.